Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
February 10, 2021 Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19 GlobeNewswire February 10, 2021 Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 More than 250,000 doses manufactured throughout Q1 2021; up to 1 million doses by mid-2021 FDA authorizes shortened infusion time for this neutralizing antibody therapy authorized for emergency use SHANGHAI, China, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ju...